Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En protokol, der sammenligner midlertidig transvenøs diafragma-pacing med standard for pleje for fravænning fra mekanisk ventilation (RESCUE 3)

20. oktober 2026 opdateret af: Lungpacer Medical Inc.

Et randomiseret, kontrolleret, åbent mærket, multicenter klinisk forsøg til evaluering af den sikre og effektive ydeevne af lungepacer-diafragma-pacing-terapisystemet hos patienter, der ikke har kunnet afvænne sig fra mekanisk ventilation.

This clinical investigation is an open-label, multi-center, randomized clinical trial (RCT) to demonstrate the safety and effective performance of the Lungpacer DPTS (plus standard of care) as compared to Control (standard of care only) in patients aged 18 years or older who are receiving mechanical ventilation. Eligible Subjects will have received mechanical ventilation for ≥96 hours (4 days) and have failed two weaning attempts.

The goal or outcome is to show a numerically greater proportion of subjects weaned in the Treatment (Lungpacer DPTS) group as compared to the Control group.

Studieoversigt

Detaljeret beskrivelse

The intended patient population is applicable for Lungpacer Diaphragm Pacing Therapy (DPT) because there are no noninvasive alternative treatments for patients who are difficult to wean from MV (i.e., ≥96 hours (4 days) on MV) or who have required prolonged MV (>7 days). The intended patient population includes approximately one-third of all patients on mechanical ventilation. Under standard of care, approximately 50% of these patients will recover from mechanical ventilation (Jung, 2016). Standard of care involves daily weaning attempts, known as Spontaneous Breathing Trials (SBTs) or Ventilator Liberation Trials (VLTs) that are intended to encourage diaphragm use and strengthening over time.Therefore, Lungpacer DPT efficacy evaluation must be compared to standard of care in a Control group. Lack of recovery from mechanical ventilation may be due to the inability of a patient to participate in VLTs or weaning attempts, due to extensive diaphragm weakness or sedation, the inability of VLTs to induce sufficient diaphragm strengthening, or co-morbidities that prevent recovery.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

223

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • Stanford, California, Forenede Stater, 94305
        • Stanford University Medical Center
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • University of Colorado Anschutz Medical Campus
    • Florida
      • Gainesville, Florida, Forenede Stater, 32610
        • University of Florida, Shands
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60612
        • Rush University Medical Center
      • Chicago, Illinois, Forenede Stater, 60611
        • Northwestern University Feinberg School of Medicine
      • Chicago, Illinois, Forenede Stater, 60612
        • U of Illinois at Chicago
      • Hines, Illinois, Forenede Stater, 60141
        • Edward Hines VA Hospital
      • Maywood, Illinois, Forenede Stater, 60153
        • Loyola University Medical Center
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46202
        • Indiana University Health Methodist Hospital
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40202
        • University of Louisville
    • Massachusetts
      • Burlington, Massachusetts, Forenede Stater, 01805
        • Lahey Hospital and Medical Center
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55407
        • Minneapolis Heart Institute Foundation
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68124
        • CHI Health Creighton University Medical Center - Bergan Mercy
    • New Jersey
      • Englewood, New Jersey, Forenede Stater, 07631
        • Englewood Hospital Medical Center
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45267
        • University of Cincinnati
      • Cleveland, Ohio, Forenede Stater, 44195
        • Cleveland Clinic Foundation
      • Columbus, Ohio, Forenede Stater, 43210
        • Ohio State University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19140
        • Temple University Hospital
    • Rhode Island
      • Warwick, Rhode Island, Forenede Stater, 02886
        • Kent County Memorial Hospital
    • South Carolina
      • Columbia, South Carolina, Forenede Stater, 29203
        • Prisma Health Baptist Hospital
    • Texas
      • Dallas, Texas, Forenede Stater, 75390
        • University of Texas Southwestern, Zale Lipshy Hospital
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84132
        • University of Utah
      • Angers, Frankrig, 49933
        • CHU Angers
      • Montpellier, Frankrig, 34295
        • CHU Montpellier
      • Paris, Frankrig, 75651
        • Hôpital La Pitié-Salpêtrière
      • Strasbourg, Frankrig, 67091
        • CHU Strasbourg
      • Berlin, Tyskland, 10117
        • Berlin Charite Mitte
      • Essen, Tyskland, 45276
        • KEM Essen
      • Löwenstein, Tyskland, 74245
        • SLK Löwenstein
      • Nuremberg, Tyskland, 90419
        • Nürnberg Klinikum Nord
      • Schmallenberg, Tyskland, 57392
        • FKKG Schmallenberg
      • Solingen, Tyskland, 42699
        • Solingen Krankenhaus Bethanien
    • Mecklenburg-Vorpommern
      • Greifswald, Mecklenburg-Vorpommern, Tyskland, 17475
        • Universitätsmedizin Greifswald

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Are 18 years or older, and,
  2. Have been mechanically ventilated for ≥96 hours (4 days), and,
  3. Have satisfied the Readiness-to-Wean criteria, and,
  4. Have failed at least 2 weaning attempts (that were conducted at least 48 hours after initiation of MV, and, that were conducted on different calendar days, and, at least one of which was the protocol-specific Ventilator Liberation Trial).

Exclusion Criteria:

  1. Maximal Inspiratory Pressure (MIP) (absolute value) >50 cm H2O;
  2. Invasive mechanical ventilation >90 days;
  3. Currently on extracorporeal membrane oxygenation (ECMO);
  4. Weaning failure due to hypervolemia;
  5. Medical history (including imaging) or known anatomy that prevents percutaneous insertion of the Catheter into the intended thoracic vein on the left side.
  6. Clinically overt congestive heart failure that is preventing weaning;
  7. Currently being treated with neuromuscular blockade;
  8. Pre-existing neurological, neuromuscular or muscular disorder that could affect the respiratory muscles;
  9. Pre-existing severe chronic pulmonary fibrosis;
  10. Pleural effusions occupying greater than one third of the pleural space on either side;
  11. BMI >45 kg/m2;
  12. Known or suspected phrenic nerve paralysis;
  13. Any electrical device (implanted or external) that may be prone to interaction with, or interference from the Lungpacer DPTS including neurological pacing/stimulator devices, cardiac pacemakers and defibrillators;
  14. Current hemodynamic instability, sepsis or septic shock;
  15. Prior bacteremia reported within the last 48 hours;
  16. Anticipating withdrawal of life support and/or shift to palliation as the goal of care;
  17. Known or suspected to be pregnant or lactating;
  18. Currently being treated in another clinical trial studying an experimental treatment that could affect the study primary outcome.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Treatment

Subject receives Lungpacer Catheter for transvenous phrenic nerve stimulation to deliver Diaphragm Pacing Therapy Sessions. DPT sessions are 6 sets of 10, delivered twice daily, for a total of 120 stimulation reps per day, plus standard of care for weaning from mechanical ventilation.

Transvenous phrenic nerve stimulation to induce diaphragm contraction.

Andre navne:
  • Lungepacer DPTS
  • AeroPace System
Ingen indgriben: Control

Subject does not receive Lungpacer Catheter or DPT. Subject receives only Standard of care for weaning from mechanical ventilation.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Successful Weaning
Tidsramme: Through Day 30

Cumulative percentage of subjects successfully weaned by Day 30.

Through Day 30
Adverse Event Profile
Tidsramme: 30 days

Characterize the adverse event profile to support an observed consistent risk profile for subjects randomized to Treatment compared to subjects randomized to Control.

Percentage of subjects with adverse events (AE) and serious adverse events (SAE) were summarized for the Treatment group and the Control group by system organ class (SOC) and lower level term.

No formal statistical hypothesis test or criterion for the primary safety endpoint was defined.

30 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Days on Mechanical Ventilation (MV)
Tidsramme: Successful weaning or Day 30

The average days on mechanical ventilation from Day 1 to removal from MV associated with successful weaning or Day 30, whichever comes first, will be statistically significantly smaller for subjects randomized to Treatment as compared to subjects randomized to Control.

Successful weaning or Day 30
Maximal Inspiratory Pressure (MIP) Change
Tidsramme: Baseline last available measure through Day 30.

The mean improvement in inspiratory muscle strength as shown by the change in Maximal Inspiratory Pressure (MIP) from randomization to last available measure in subjects randomized to Treatment is superior to that in subjects randomized to Control.

Baseline last available measure through Day 30.
Rapid Shallow Breathing Index (RSBI) Change
Tidsramme: Baseline to last available measure through Day 30.

To determine change in Rapid Shallow Breathing Index (RSBI) from randomization to last available measure in subjects randomized to Treatment as compared to Control. RSBI measures the ratio of the respiratory rate to Tidal Volume in breaths/min/L and is commonly used as an index for weaning success. A reduction in RSBI is considered as clinical improvement.

Baseline to last available measure through Day 30.
Survival
Tidsramme: 30 days

Cumulative percentage of subjects who survived through Day 30.

30 days

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Re-instatements of MV (After Successful Weaning) Through Day 30.
Tidsramme: Through Day 30.

Assessment of re-instatements of MV in subjects who were successful weaned through Day 30 in the Treatment group as compared to the Control group.

Through Day 30.
Tracheotomy After Randomization
Tidsramme: Through 30 days

Assessment of percentage of subjects after randomization to Day 30 that required tracheostomy in the Treatment group as compared to the Control group.

Through 30 days
ICU Discharges to Day 30.
Tidsramme: through 30 days

Assessment of ICU discharges to Day 30 in the Treatment group as compared to the Control group.

through 30 days
Hospital Discharges to Day 30.
Tidsramme: through 30 days

Assessment of hospital admissions and discharges to Day 30 in the Treatment group as compared to the Control group.

through 30 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

14. juni 2019

Primær færdiggørelse (Faktiske)

28. december 2022

Studieafslutning (Faktiske)

27. januar 2023

Datoer for studieregistrering

Først indsendt

19. december 2018

Først indsendt, der opfyldte QC-kriterier

19. december 2018

Først opslået (Faktiske)

21. december 2018

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

20. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Only investigators participating in this clinical trial will be able to see final de-identified participant data at the completion of the study.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner